Women with advanced breast cancer given the Nektar Therapeutics Inc. drug NKTR-102 (etirinotecan pegol) after earlier cancer treatments lived just 2.1 months longer than those treated with a chemotherapy chosen by their doctors, missing the phase III study's primary endpoint. While subsets of patients fared better, the study failed to achieve statistical significance on primary and secondary endpoints.